26 Sep 2025 | 5 Mins Read
Indian pharma under threat from US tariff hike
Flipitmoney
Indian pharmaceutical companies, including Sun Pharma and Wockhardt, may face risks from a US plan to impose 100% tariffs on branded and patented drugs. While Indian generic drugmakers are not directly targeted, they may still be affected if the tariffs expand. Key listed companies may see up to 15% revenue impact, with Biocon facing challenges due to biosimilars ambiguity.